Inventiva, a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses and other diseases, announced the initiation of its NATiV3 Phase III clinical trial evaluating lanifibranor for the treatment of NASH.
[Inventiva]
7992332
{7992332:nan}
apa
50
1
166604
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
